Investors
Invest in InDex
Pharmaceuticals
-
Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
June 1, 2022 Regulatory
-
InDex Pharmaceuticals Holding AB (publ) interim report January – March 2022
May 16, 2022 Regulatory
InDex Pharmaceuticals Holding AB (publ) published its interim report Q1 for January-March 2022 on May 16, 2021 at 08:00 a.m. CEST.
-
Interim Report Q2 2022
-
Interim Report Q3 2022
-
Year-end Report 2022
InDex Pharmaceuticals in numbers
-
15-30
The most common age of an ulcerative colitis diagnosis
-
2 Million
Patients living with ulcerative colitis in the US and Europe
-
7.5 billion USD
Total yearly sales of medications for ulcerative colitis
-
12 billion USD
The estimated total yearly sales of medication for ulcerative colitis in 2026
InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis.
Investor contact
